NR4A1 and neoplasm: In addition, sociodemographic and clinical inequities in trastuzumab receipt are highlighted in an older systematic review of observational studies; receipt was higher in women who were younger, had fewer comorbidities, a higher tumor grade, a larger tumor size, an advanced stage cancer, and a negative hormone receptor status (20).